Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pharming Group N.V (PHAR) Accounts Payables: 2019-2025

Historic Accounts Payables for Pharming Group N.V (PHAR) over the last 5 years, with Sep 2025 value amounting to $78.2 million.

  • Pharming Group N.V's Accounts Payables rose 7.69% to $78.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $78.2 million, marking a year-over-year increase of 7.69%. This contributed to the annual value of $66.6 million for FY2024, which is 8.16% down from last year.
  • As of Q3 2025, Pharming Group N.V's Accounts Payables stood at $78.2 million, which was down 0.21% from $78.4 million recorded in Q2 2025.
  • Pharming Group N.V's 5-year Accounts Payables high stood at $78.4 million for Q2 2025, and its period low was $42,744 during Q3 2022.
  • For the 3-year period, Pharming Group N.V's Accounts Payables averaged around $68.5 million, with its median value being $68.7 million (2025).
  • As far as peak fluctuations go, Pharming Group N.V's Accounts Payables tumbled by 99.90% in 2022, and later surged by 146,212.93% in 2023.
  • Quarterly analysis of 5 years shows Pharming Group N.V's Accounts Payables stood at $42.5 million in 2021, then climbed by 28.23% to $54.5 million in 2022, then soared by 33.16% to $72.5 million in 2023, then dropped by 8.16% to $66.6 million in 2024, then rose by 7.69% to $78.2 million in 2025.
  • Its Accounts Payables stands at $78.2 million for Q3 2025, versus $78.4 million for Q2 2025 and $68.7 million for Q1 2025.